Stratos Wealth Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Stratos Wealth Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,181	Closed	-$341K	–	1382
2024 Q4	$341K	Sell	5,181 -241	-4%	-$16.1K	﹤0.01%	1091
2024 Q3	$381K	Sell	5,422 -4	-0.1%	-$334	0.01%	1041
2024 Q2	$447K	Hold	5,426	–	–	0.01%	942
2024 Q1	$474K	Sell	5,426 -283	-5%	-$25.3K	0.01%	917
2023 Q4	$550K	Buy	5,709 +115	+2%	+$10.2K	0.01%	840
2023 Q3	$495K	Buy	+5,594	New	+$498K	0.01%	822
2018 Q4	–	Sell	-498	Closed	-$48K	–	1004
2018 Q3	$48K	Buy	+498	New	+$49.7K	﹤0.01%	1475
2018 Q2	–	Sell	-512	Closed	-$42K	–	1148
2018 Q1	$42K	Buy	512 +325	+174%	+$27.9K	﹤0.01%	1664
2017 Q4	$17K	Buy	+187	New	+$16.3K	﹤0.01%	1961

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $20.1B AUM 60.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stratos Wealth Partners's BMRN Position: Q1 2025 in Review

Stratos Wealth Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2025, closing a stake of 5,181 shares — an estimated $341K sold.

Stratos Wealth Partners first reported a position in BMRN in Q4 2017 and held it in 9 quarters. The position peaked at $550K in Q4 2023. 584 funds tracked by Wall St. Rank hold BMRN as of Q1 2025.

Stratos Wealth Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Stratos Wealth Partners sold 5,181 BioMarin Pharmaceuticals shares in Q1 2025, an estimated $341K.
Stratos Wealth Partners first reported a position in BioMarin Pharmaceuticals in Q4 2017 and held it in 9 quarters.
Stratos Wealth Partners's BioMarin Pharmaceuticals position peaked at $550K in Q4 2023.
584 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2025.

Based on Stratos Wealth Partners's 13F filing for Q1 2025, filed 30 Apr 2025.